Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

Key Takeaways

• First-in-human Phase 1/2a trial launches for GLIX1.
• GLIX1 activates TET2, inducing tumor-selective DNA damage.
• Preclinical data show brain penetration and favorable safety.
• Trial includes NYU, Northwestern, Moffitt; data expected 2027.
• Potential synergy with PARP inhibitors explored in expansion.

Pulse Analysis

Glioblastoma multiforme remains the deadliest primary brain tumor in the United States, with median survival under 15 months despite surgery, radiation, and temozolomide. A growing body of research links the loss of TET2 activity to the aggressive phenotype of GBM, opening a therapeutic window for epigenetic restoration. Hemispherian’s GLIX1 is the first small‑molecule designed to reactivate TET2, thereby provoking tumor‑selective DNA damage while sparing normal tissue. The oral formulation and demonstrated blood‑brain barrier penetration differentiate it from conventional chemotherapies and set the stage for a novel treatment paradigm.

The Phase 1/2a study (NCT07464925) will enroll up to 30 patients with recurrent or progressive GBM and other high‑grade gliomas across NYU Langone, Northwestern University and Moffitt Cancer Center. Primary endpoints focus on safety, maximum tolerated dose, pharmacokinetics and early efficacy signals, with data expected by mid‑2027. An expansion Phase 2a will explore newly diagnosed cohorts and combine GLIX1 with PARP inhibitors, leveraging synthetic lethality to amplify DNA repair stress. By integrating academic expertise and a clear dose‑escalation schema, the trial aims to validate a differentiated mechanism that could complement existing standards of care.

If GLIX1 demonstrates safety and early activity, it could reshape the glioblastoma pipeline, which currently lacks any FDA‑approved targeted agents beyond tumor‑treating fields. Hemispherian’s partnership with BioLineRx provides both funding and translational expertise, positioning the company for rapid follow‑on studies in other solid tumors where TET2 suppression is documented. 5 billion neuro‑oncology segment. The trial also underscores a broader industry shift toward DNA‑damage response modulation as a therapeutic strategy.